KR20180008397A - 신경조절 장치 - Google Patents
신경조절 장치 Download PDFInfo
- Publication number
- KR20180008397A KR20180008397A KR1020177026793A KR20177026793A KR20180008397A KR 20180008397 A KR20180008397 A KR 20180008397A KR 1020177026793 A KR1020177026793 A KR 1020177026793A KR 20177026793 A KR20177026793 A KR 20177026793A KR 20180008397 A KR20180008397 A KR 20180008397A
- Authority
- KR
- South Korea
- Prior art keywords
- signal
- nerve
- patient
- vagus nerve
- waveform
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000003767 neural control Effects 0.000 title claims description 45
- 210000001186 vagus nerve Anatomy 0.000 claims abstract description 153
- 238000000034 method Methods 0.000 claims abstract description 86
- 206010006482 Bronchospasm Diseases 0.000 claims abstract description 71
- 230000007885 bronchoconstriction Effects 0.000 claims abstract description 59
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 48
- 210000005036 nerve Anatomy 0.000 claims description 189
- 230000001537 neural effect Effects 0.000 claims description 143
- 230000036982 action potential Effects 0.000 claims description 69
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 44
- 208000006673 asthma Diseases 0.000 claims description 42
- 210000005091 airway smooth muscle Anatomy 0.000 claims description 41
- 230000008035 nerve activity Effects 0.000 claims description 35
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 24
- 230000005764 inhibitory process Effects 0.000 claims description 24
- 239000008280 blood Substances 0.000 claims description 23
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000000835 fiber Substances 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 20
- 230000001734 parasympathetic effect Effects 0.000 claims description 19
- 210000004072 lung Anatomy 0.000 claims description 16
- 206010011224 Cough Diseases 0.000 claims description 12
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 12
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 12
- 239000001569 carbon dioxide Substances 0.000 claims description 12
- 230000003287 optical effect Effects 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 208000013116 chronic cough Diseases 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 11
- 230000036961 partial effect Effects 0.000 claims description 11
- 210000002569 neuron Anatomy 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 230000001052 transient effect Effects 0.000 claims description 8
- 230000001276 controlling effect Effects 0.000 claims description 7
- 230000001066 destructive effect Effects 0.000 claims description 7
- 210000001147 pulmonary artery Anatomy 0.000 claims description 7
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 6
- 230000003447 ipsilateral effect Effects 0.000 claims description 6
- 150000003431 steroids Chemical group 0.000 claims description 6
- 230000036387 respiratory rate Effects 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 238000002513 implantation Methods 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 3
- 229940092705 beclomethasone Drugs 0.000 claims description 3
- 229960004436 budesonide Drugs 0.000 claims description 3
- 229960000289 fluticasone propionate Drugs 0.000 claims description 3
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 3
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 3
- 229960001664 mometasone Drugs 0.000 claims 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 53
- 230000000903 blocking effect Effects 0.000 description 25
- 206010057190 Respiratory tract infections Diseases 0.000 description 16
- 210000004126 nerve fiber Anatomy 0.000 description 15
- 230000008602 contraction Effects 0.000 description 14
- 208000009079 Bronchial Spasm Diseases 0.000 description 12
- 208000014181 Bronchial disease Diseases 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 238000004891 communication Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 5
- 210000000621 bronchi Anatomy 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 229930003347 Atropine Natural products 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 4
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 4
- 229960000396 atropine Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 230000006461 physiological response Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000004007 neuromodulation Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 230000001515 vagal effect Effects 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003435 bronchoconstrictive effect Effects 0.000 description 2
- 230000007883 bronchodilation Effects 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 238000009924 canning Methods 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 238000013479 data entry Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011554 guinea pig model Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- QAMFBRUWYYMMGJ-UHFFFAOYSA-N hexafluoroacetylacetone Chemical compound FC(F)(F)C(=O)CC(=O)C(F)(F)F QAMFBRUWYYMMGJ-UHFFFAOYSA-N 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000005037 parasympathetic nerve Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010005052 Bladder irritation Diseases 0.000 description 1
- 102000017063 Catecholamine Receptors Human genes 0.000 description 1
- 108010013659 Catecholamine Receptors Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 1
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008579 epileptogenesis Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000003794 neural signal transduction Effects 0.000 description 1
- 230000007372 neural signaling Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000003227 neuromodulating effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 1
- 229940032712 succinylcholine Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/007—Heating or cooling appliances for medical or therapeutic treatment of the human body characterised by electric heating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0551—Spinal or peripheral nerve electrodes
- A61N1/0553—Paddle shaped electrodes, e.g. for laminotomy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/205—Applying electric currents by contact electrodes continuous direct currents for promoting a biological process
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3601—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of respiratory organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36053—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for vagal stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/3611—Respiration control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36135—Control systems using physiological parameters
- A61N1/36139—Control systems using physiological parameters with automatic adjustment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
- A61N1/36167—Timing, e.g. stimulation onset
- A61N1/36171—Frequency
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
- A61N1/36167—Timing, e.g. stimulation onset
- A61N1/36178—Burst or pulse train parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0622—Optical stimulation for exciting neural tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/007—Heating or cooling appliances for medical or therapeutic treatment of the human body characterised by electric heating
- A61F2007/0075—Heating or cooling appliances for medical or therapeutic treatment of the human body characterised by electric heating using a Peltier element, e.g. near the spot to be heated or cooled
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36189—Control systems using modulation techniques
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0021—Neural system treatment
- A61N2007/0026—Stimulation of nerve tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/067—Radiation therapy using light using laser light
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Electrotherapy Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Surgical Instruments (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562119998P | 2015-02-24 | 2015-02-24 | |
| US62/119,998 | 2015-02-24 | ||
| PCT/US2016/019234 WO2016138066A1 (en) | 2015-02-24 | 2016-02-24 | Neuromodulation device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180008397A true KR20180008397A (ko) | 2018-01-24 |
Family
ID=56789175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177026793A Withdrawn KR20180008397A (ko) | 2015-02-24 | 2016-02-24 | 신경조절 장치 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10441787B2 (enExample) |
| EP (2) | EP3261711B1 (enExample) |
| JP (1) | JP2018508329A (enExample) |
| KR (1) | KR20180008397A (enExample) |
| CN (1) | CN107847740A (enExample) |
| AU (1) | AU2016222825A1 (enExample) |
| BR (1) | BR112017018068A2 (enExample) |
| CA (1) | CA2977517A1 (enExample) |
| ES (1) | ES2855799T3 (enExample) |
| RU (1) | RU2017129539A (enExample) |
| WO (1) | WO2016138066A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10029101B2 (en) | 2013-01-09 | 2018-07-24 | Mayo Foundation For Medical Education And Research | Systems for the detection and delivery of neurochemical and electrical signals for functional restoration |
| AU2015237140A1 (en) * | 2014-03-27 | 2016-10-13 | Circuit Therapeutics, Inc. | System and method for therapeutic management of cough |
| KR102445887B1 (ko) | 2016-04-21 | 2022-09-21 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법 |
| US11040197B2 (en) * | 2017-06-22 | 2021-06-22 | Mayo Foundation For Medical Education And Research | Voltammetric neurochemical detection in whole blood |
| CN109199359A (zh) * | 2018-10-15 | 2019-01-15 | 暨南大学 | 光电联合刺激系统和光电联合刺激神经纤维方法 |
| US11077314B1 (en) * | 2020-04-29 | 2021-08-03 | Multi Radiance Medical | System and method for treating patients requiring mechanical ventilation |
| DE102020114745A1 (de) * | 2020-06-03 | 2021-12-09 | NeuroCare Group GmbH | Körperzustandsabhängige Stimulation mit Echtzeitkommunikation zwischen einem Aktions- und einem Erfassungsmodul |
| WO2025079630A1 (ja) * | 2023-10-13 | 2025-04-17 | 帝人ファーマ株式会社 | 咳嗽治療装置 |
| EP4635557A1 (en) | 2024-04-16 | 2025-10-22 | Merck Patent GmbH | System for inhibiting action potential conduction in a nerve |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002065896A2 (en) * | 2001-02-20 | 2002-08-29 | Case Western Reserve University | Systems and methods for reversibly blocking nerve activity |
| US6928320B2 (en) * | 2001-05-17 | 2005-08-09 | Medtronic, Inc. | Apparatus for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated |
| US20060200219A1 (en) * | 2005-03-01 | 2006-09-07 | Ndi Medical, Llc | Systems and methods for differentiating and/or identifying tissue regions innervated by targeted nerves for diagnostic and/or therapeutic purposes |
| US8660647B2 (en) * | 2005-07-28 | 2014-02-25 | Cyberonics, Inc. | Stimulating cranial nerve to treat pulmonary disorder |
| EP1948301B8 (en) * | 2005-11-10 | 2014-03-12 | ElectroCore LLC | Electrical stimulation treatment of bronchial constriction |
| US8874227B2 (en) * | 2009-03-20 | 2014-10-28 | ElectroCore, LLC | Devices and methods for non-invasive capacitive electrical stimulation and their use for vagus nerve stimulation on the neck of a patient |
| US9037247B2 (en) * | 2005-11-10 | 2015-05-19 | ElectroCore, LLC | Non-invasive treatment of bronchial constriction |
| US7711430B2 (en) * | 2006-02-10 | 2010-05-04 | Electrocore Llc | Methods and apparatus for treating anaphylaxis using electrical modulation |
| US9579506B2 (en) * | 2008-01-25 | 2017-02-28 | Flint Hills Scientific, L.L.C. | Contingent cardio-protection for epilepsy patients |
| WO2009137819A1 (en) * | 2008-05-09 | 2009-11-12 | Innovative Pulmonary Solutions, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
| US8918178B2 (en) * | 2009-03-20 | 2014-12-23 | ElectroCore, LLC | Non-invasive vagal nerve stimulation to treat disorders |
| US9833621B2 (en) * | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| CA2795564C (en) * | 2010-04-06 | 2021-06-15 | Innovative Pulmonary Solutions, Inc. | System and method for pulmonary treatment |
| US9358381B2 (en) * | 2011-03-10 | 2016-06-07 | ElectroCore, LLC | Non-invasive vagal nerve stimulation to treat disorders |
| WO2012159002A2 (en) * | 2011-05-19 | 2012-11-22 | Neuros Medical, Inc. | High-frequency electrical nerve block |
| US9398933B2 (en) * | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
| US20140324129A1 (en) * | 2013-04-30 | 2014-10-30 | Case Western Reserve University | Systems and methods for temporary, incomplete, bi-directional, adjustable electrical nerve block |
| US10639477B2 (en) * | 2014-01-17 | 2020-05-05 | Cardiac Pacemakers, Inc. | Systems and methods for delivering pulmonary therapy |
-
2016
- 2016-02-24 ES ES16756233T patent/ES2855799T3/es active Active
- 2016-02-24 EP EP16756233.9A patent/EP3261711B1/en not_active Not-in-force
- 2016-02-24 EP EP20212912.8A patent/EP3808407A1/en not_active Withdrawn
- 2016-02-24 BR BR112017018068-5A patent/BR112017018068A2/pt not_active Application Discontinuation
- 2016-02-24 CA CA2977517A patent/CA2977517A1/en not_active Abandoned
- 2016-02-24 US US15/552,475 patent/US10441787B2/en active Active
- 2016-02-24 CN CN201680023560.6A patent/CN107847740A/zh active Pending
- 2016-02-24 KR KR1020177026793A patent/KR20180008397A/ko not_active Withdrawn
- 2016-02-24 WO PCT/US2016/019234 patent/WO2016138066A1/en not_active Ceased
- 2016-02-24 AU AU2016222825A patent/AU2016222825A1/en not_active Abandoned
- 2016-02-24 JP JP2017562969A patent/JP2018508329A/ja active Pending
- 2016-02-24 RU RU2017129539A patent/RU2017129539A/ru not_active Application Discontinuation
-
2019
- 2019-09-05 US US16/562,139 patent/US20200009384A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3808407A1 (en) | 2021-04-21 |
| JP2018508329A (ja) | 2018-03-29 |
| AU2016222825A1 (en) | 2017-09-07 |
| US20180043162A1 (en) | 2018-02-15 |
| CA2977517A1 (en) | 2016-09-01 |
| EP3261711A4 (en) | 2019-02-20 |
| BR112017018068A2 (pt) | 2018-04-10 |
| WO2016138066A1 (en) | 2016-09-01 |
| EP3261711B1 (en) | 2020-12-16 |
| EP3261711A1 (en) | 2018-01-03 |
| RU2017129539A (ru) | 2019-03-25 |
| ES2855799T3 (es) | 2021-09-24 |
| US20200009384A1 (en) | 2020-01-09 |
| CN107847740A (zh) | 2018-03-27 |
| US10441787B2 (en) | 2019-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20180008397A (ko) | 신경조절 장치 | |
| US9731134B2 (en) | Neuromodulatory method for treating chronic or refractory rhinitis | |
| CA2865410C (en) | System and method to modulate phrenic nerve to prevent sleep apnea | |
| US20140039450A1 (en) | Method and Apparatus for Treating Respiratory Disease | |
| CN101674862A (zh) | 支气管收缩的电刺激治疗 | |
| US12083342B2 (en) | Neuromodulation device | |
| US20130274824A1 (en) | Neuromodulatory method for treating chronic rhinosinusitis | |
| US20240131327A1 (en) | Neuromodulation Device | |
| US20150251008A1 (en) | Neuromodulatory devices, systems, and methods for treating fibromyalgia | |
| JP2018523542A5 (enExample) | ||
| Erokhin et al. | Phrenic nerve stimulation in complex rehabilitation for cervical spinal cord injury using modified implantable device (case report) | |
| CN103949010A (zh) | 高频电流在治疗阻塞性睡眠呼吸暂停综合征的应用 | |
| US20190201692A1 (en) | Treatment of conditions associated with impaired glucose control | |
| Velazco et al. | Phrenic nerve pacing: current concepts | |
| Sepulveda et al. | Treatment of asthmatic bronchoconstriction by percutaneous low voltage vagal nerve stimulation: case report | |
| Hillen et al. | Peripheral Nerve Interface Applications, Respiratory Pacing | |
| Surani | Diaphragmatic Pacemaker |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20170922 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination |